Axsome Therapeutics (AXSM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.99
- Estimate
- -$0.84
- Surprise
- -17.2%
- Revenue (period 2026-06-30)
- $218.4M
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Axsome Therapeutics (AXSM) reported a wider loss than forecast — diluted EPS of -$0.99 against the -$0.84 estimate (a 17.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AXSM Sell at 5.5/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -17.2% surprise compares with a -13.4% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Quality below floor (3.7 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $220.75
- Price target
- $256.88
- Stop
- $207.21
- Upside to target
- +16.4%
- Reward-to-risk
- 1.5:1
Risk check: trading volume is running 2.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
AXSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $11.56B
- P/E (fwd)
- 43.9
- 52-week range
- $112.90–$260.19
- Off 52-week high
- 15.2%
- RSI (14)
- 66
- Volume vs avg
- 2.20×
- Score today
- 5.5/10